IP Library Granted Patent US 10,093,896
Granted Patent B2
US 10,093,896 · App. 13/147,221 · Granted Oct 9, 2018

Methods of generating tissue using devitalized, acellular scaffold matrices derived from micro-organs

Inventor: Eduardo N. Mitrani (Jerusalem, IL)
Assignee: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
C12N5/0068A61L27/3604A61L27/3804C12N5/0606C12N5/067C12N5/0676C12N5/0677C12N5/0689A61K35/12C12N2506/02C12N2533/90
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,093,896
App. No.
13/147,221
Granted
Oct 9, 2018
Kind
B2
Abstract

A composition of matter is provided comprising a devitalized, acellular tissue-derived scaffold seeded with differentiated cells, particularly pancreatic islet cells, wherein the cells can maintain cell-specific function or structure in culture on the scaffold. Methods of generating same and uses thereof are also provided.

Claims (8)

1. A composition of matter comprising (i) a devitalized, acellular, lung tissue-derived three dimensional scaffold having dimensions selected such that the point deepest within said scaffold is at least about 100 micrometers and not more than about 225 micrometers away from the nearest surface of the scaffold and (ii) whole pancreatic islets seeded and cultured on said acelluar three dimensional scaffold and maintaining glucose-responsive insulin secretion when cultured on said scaffold after at least 7 days of culture on said scaffold.

2. The composition of matter of claim 1 , wherein said seeded pancreatic islets are cultured pancreatic islets.

3. The composition of matter of claim 1 , wherein said pancreatic islets express at least one islet cell-specific protein selected from the group consisting of insulin, Glut2 and Pdx1 after at least 7 days in culture on said scaffold.

4. The composition of matter of claim 3 , wherein said pancreatic islets express Glut2 or Pdx1 following at least 7 days of culture on the scaffold.

5. A method of generating the composition of matter of claim 1 , the method comprising seeding said differentiated cells on said scaffold.

6. A pharmaceutical composition comprising the composition of matter of claim 1 and a pharmaceutically acceptable carrier.

7. A method of treating diabetes in a subject, comprising transplanting a therapeutically effective amount of the composition of matter of claim 1 into the subject, thereby treating diabetes.

8. A method of producing a pancreatic islet-cell specific protein comprising in-vitro culturing the composition of matter of claim 1 under conditions which promote cell growth and proliferation, and isolating said islet cell-specific protein from said culture.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 23, 2011
From: MITRANI, EDUARDO N.
To: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Reel/Frame 027103/0501 →
Priority Claims (1)
IL 196820 · Feb 1, 2009 · national
Continuity (2)
Provisional Application 61202307 · Feb 17, 2009
Related Publication 20110287071A1 · Nov 24, 2011